date,title,source
Oct-17-18,Duchenne biotech Sarepta to open gene therapy facility in Ohio,American City Business Journals
Oct-17-18,Sarepta Therapeutics (SRPT) Q3 Earnings Preview: What to Expect,Zacks
Oct-17-18,Sarepta Announces Agreement With Lysogene for Gene Therapy,Zacks
Oct-18-18,"Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018",GlobeNewswire
Oct-23-18,"Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT",Zacks
Oct-24-18,"Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Oct-24-18,Sarepta Therapeutics: 3Q Earnings Snapshot,Associated Press
Oct-24-18,Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments,GlobeNewswire
Oct-24-18,Q3 Earnings Preview For Sarepta Therapeutics,Benzinga
Oct-25-18,Edited Transcript of SRPT earnings conference call or presentation 24-Oct-18 8:30pm GMT,Thomson Reuters StreetEvents
Oct-25-18,"Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up",Zacks
Oct-26-18,Edited Transcript of SRPT earnings conference call or presentation 24-Oct-18 8:30pm GMT,Thomson Reuters StreetEvents
Oct-29-18,7 Rising Healthcare Stocks to Consider,InvestorPlace
Oct-30-18,Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares,GuruFocus.com
Oct-30-18,"Report: Exploring Fundamental Drivers Behind Sarepta Therapeutics, Reinsurance Group of America, Illinois Tool Works, ATN International, Morningstar, and Hubbell  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Oct-31-18,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Oct-31-18,Today's Research Reports on Trending Tickers: bluebird bio and Sarepta Therapeutics,ACCESSWIRE
Nov-05-18,Weekly CEO Buys Highlight,GuruFocus.com
Nov-06-18,Hedge Funds Just Stormed Into This Red-Hot Biotech Company,Insider Monkey
Nov-06-18,Implied Volatility Surging for Sarepta Therapeutics (SPRT) Stock Options,Zacks
Nov-07-18,"Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock",GlobeNewswire
Nov-08-18,"Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock",GlobeNewswire
Nov-12-18,These Biopharmas Could Cure Genetic Diseases  At $5 Million Apiece,Investor's Business Daily
Nov-16-18,Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics,ACCESSWIRE
Nov-23-18,Sarepta Stock More Than Doubles This Year So Far: Here's Why,Zacks
Nov-30-18,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Dec-06-18,Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics,ACCESSWIRE
Dec-07-18,"New Research Coverage Highlights Callaway Golf, Synchrony Financial, Roper Technologies, Ringcentral, Sarepta Therapeutics, and Advanced Micro Devices  Consolidated Revenues, Company Growth, and Expectations for 2018",GlobeNewswire
Dec-11-18,"Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors",GlobeNewswire
Dec-12-18,"Analysts Expect Breakeven For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)",Simply Wall St.
Dec-13-18,"Ghost Tree Capitals AUM, Returns and Holdings",Insider Monkey
Dec-20-18,Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53,GlobeNewswire
Dec-24-18,Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019,Investor's Business Daily
Dec-31-18,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Jan-02-19,Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy,GlobeNewswire
Jan-02-19,Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference,GlobeNewswire
Jan-03-19,Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply,Zacks
Jan-04-19,Here's Why Sarepta Therapeutics Fell 15.7% in December,Motley Fool
Jan-08-19,"Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track",Benzinga
Jan-08-19,4 Biotechs That Are Potential Buyouts Post Celgene Deal,Zacks
Jan-11-19,Why Sarepta Therapeutics Stock Is Starting to Shine Again,InvestorPlace
Jan-14-19,"Analysis: Positioning to Benefit within Alphabet, Globalstar, Ingevity, Vocera Communications, Sarepta Therapeutics, and FLIR  Research Highlights Growth, Revenue, and Consolidated Results",GlobeNewswire
Jan-15-19,Heres your guide to the upcoming biotechnology takeover wave,MarketWatch
Jan-15-19,FDA pilot program could help Wave avoid orphan-drug pitfalls,American City Business Journals
Jan-16-19,Here are top analysts' 5 favorite growth stocks for 2019,CNBC
Jan-31-19,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Jan-31-19,Fear of Missing Out Is the Main Driving Force in This Market,TheStreet.com
Jan-31-19,"Your first trade for Thursday, January 31",CNBC
Jan-31-19,Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics,ACCESSWIRE
Feb-01-19,"Should You Take Comfort From Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?",Simply Wall St.
Feb-01-19,6 Biotech Stocks to Watch Now,Motley Fool
Feb-05-19,Weekly CFO Sells Highlight,GuruFocus.com
Feb-07-19,What Solid Biosciences' First Failure Means for Sarepta Therapeutics,Motley Fool
Feb-07-19,Solid Biosciences shares drop 70% on disappointing Duchenne data,American City Business Journals
Feb-07-19,Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains,Bloomberg
Feb-11-19,Weekly CFO Sells Highlight,GuruFocus.com
Feb-11-19,Implied Volatility Surging for Sarepta (SRPT) Stock Options,Zacks
Feb-14-19,"Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)",GlobeNewswire
Feb-14-19,Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53,GlobeNewswire
